

Covariate adjusted measures of diagnostic accuracy based on pooled biomarkers

Christopher McMahan

Collaborators: Alexander McLain, Colin Gallagher, and Enrique Schisterman

October 13, 2016

Biological marker (or biomarker) evaluation

- ❑ The motivation behind evaluating new biomarkers:
 - ❑ Identify new markers that can be used to assess exposures
 - ❑ Identify new markers for disease detection
- ❑ In 2011, 70% of the original articles in *Clinical Chemistry*, were focused on biomarker evaluation; Boyd et al. (2012)
 - ❑ HIV; Kanekar (2010)
 - ❑ Cancer; Borges et al. (2013)
 - ❑ Cardiovascular disease; Sabatine et al. (2012)
 - ⋮
- ❑ This area of epidemiological research is often limited due to the cost associated with measuring biomarker levels
 - ❑ Caudill (2012) reported a cost of \$1400 per specimen to obtain a single analytical measurement of 61 polychlorinated and 13 polybrominated compounds
- ❑ If you know me, you would know how I would solve this problem, more on this shortly


Biomarker evaluation: Measures of discriminatory ability

- ❑ Several common measures:
 - ❑ Receiver operating characteristic (ROC) curve
 - ❑ Area under the ROC curve (AUC)
 - ❑ Youden Index (YI)
- ❑ Let f_{C^-} and f_{C^+} denote the probability distribution functions for the biomarker levels associated with cases and controls, respectively
- ❑ Consider a test that diagnoses a subject as positive if their biomarker level is above a threshold t

$$\text{Sensitivity: } S_e(t) = P(\text{test } + \mid \text{truly } +) = \int_t^\infty f_{C^+}(c)dc$$

$$\text{Specificity: } S_p(t) = P(\text{test } - \mid \text{truly } -) = \int_\infty^t f_{C^-}(c)dc$$


Measures of discriminatory ability



- ❑ f_{c+} (f_{c-}) denoted by the red (black) curve
- ❑ t denoted by the yellow line
- ❑ $S_e(t)$ ($S_p(t)$) denoted by the dark (light) blue shaded region

Receiver operating characteristic (ROC) curve


Construction: Plot $S_e(t)$ versus $1 - S_p(t)$, for all t



- ❑ If the ROC curve (red) is “far” from the chance line (black) then the biomarker is a good discriminator
- ❑ If the ROC curve (red) is “close” to the chance line (black) then the biomarker is not a useful discriminator

Area under the ROC curve (AUC)


Calculation: $AUC = P(C^+ > C^-)$, where $C^+ \sim f_{C^+}$, $C^- \sim f_{C^-}$



- ❑ If $AUC \approx 1$, then the biomarker is a good discriminator
- ❑ If $AUC \approx 0.5$, then the biomarker is not a useful discriminator

Youden index (YI): Youden (1950)

Calculation: $YI = \sup_{t \in \mathbb{R}} \{S_e(t) + S_p(t) - 1\}$



- ❑ YI is the maximum vertical distance (blue) between the ROC curve (red) and the chance line (black)
- ❑ If $YI \approx 1(0)$, then the biomarker is an (in)effective discriminator

Pooled biomarker evaluation

- ❑ Pooling: A means to reduce testing cost
 - ❑ Physically combine several specimens into a pool and then measure the pool for the characteristic of interest
 - ❑ If one uses pools of size c , then N specimens can be assessed at the cost of $J = N/c$ measurements; i.e. at a drastic reduction in testing cost
- ❑ Dorfman (1943) originally proposed pool (group) testing
- ❑ Group testing has been used in many venues:
 - ❑ Infectious disease screening:
 - ❑ HIV, HBV, and HCV; Stramer et al. (2013)
 - ❑ Chlamydia and gonorrhea; Lindan et al. (2005)
 - ❑ Identifying lead compounds in drug discovery; Remlinger et al. (2006)
 - ❑ Screening for viral agents in the case of bioterrorism; Schmidt et al. (2005)
 - ❑ Detecting rare mutations in genetics; Gastwirth (2000)

Pooled biomarker evaluation

- ❑ Several authors have investigated the use of pooled assessments to evaluate the discriminatory ability of a biomarker of interest
 - ❑ Faraggi et al. (2003)
 - ❑ Liu and Schisterman (2003)
 - ❑ Mumford et al. (2006)
 - ❑ Bondell et al. (2007)
 - ❑ Vexler et al. (2008)
 - ❑ Malinovsky et al. (2012)
- ❑ Regretfully, all of these techniques have failed to acknowledge confounding factors (e.g., age, sex, gender, race, etc.)
- ❑ The focus of this work is to develop methods of estimating covariate dependent ROC curves, AUCs, and Youden indices based on pooled biomarker assessments

Control model:

$$Y_{ij-} = \mathbf{X}'_{ij-}\boldsymbol{\beta}_- + \epsilon_{ij-}, \text{ for } i = 1, \dots, c_- \text{ and } j = 1, \dots, J_-$$

Case model:

$$Y_{ij+} = \mathbf{X}'_{ij+}\boldsymbol{\beta}_+ + \epsilon_{ij+}, \text{ for } i = 1, \dots, c_+ \text{ and } j = 1, \dots, J_+$$

where,

- Y_{ij-} (Y_{ij+}) are the biomarker levels of the controls (cases)
- \mathbf{X}_{ij-} (\mathbf{X}_{ij+}) is a p -dimensional vector of covariates
- $\boldsymbol{\beta}_-$ ($\boldsymbol{\beta}_+$) is a vector of regression parameters
- $\epsilon_{ij-} \stackrel{iid}{\sim} N(0, \sigma_-^2)$ and $\epsilon_{ij+} \stackrel{iid}{\sim} N(0, \sigma_+^2)$

Note: When pooled assessments are being made the individual level biomarker levels (i.e., Y_{ij-} and Y_{ij+}) are unobservable

Models, notation, and assumptions

Assumption: The aggregated, observed, pool response is the arithmetic average of the individuals biomarker levels

The models for the observed pooled assessments are

Control model:

$$Y_{j-} = \frac{1}{c_-} \sum_{i=1}^{c_-} Y_{ij-} = \bar{\mathbf{X}}_{j-}' \boldsymbol{\beta}_- + \epsilon_{j-}, \text{ for } j = 1, \dots, J_-$$

Case model:

$$Y_{j+} = \frac{1}{c_+} \sum_{i=1}^{c_+} Y_{ij+} = \bar{\mathbf{X}}_{j+}' \boldsymbol{\beta}_+ + \epsilon_{j+}, \text{ for } j = 1, \dots, J_+$$

where,

$$\square \bar{\mathbf{X}}_{j-} = c_-^{-1} \sum_{i=1}^{c_-} \mathbf{X}_{ij-} \text{ and } \bar{\mathbf{X}}_{j+} = c_+^{-1} \sum_{i=1}^{c_+} \mathbf{X}_{ij+}$$

$$\square \epsilon_{j-} \stackrel{iid}{\sim} N(0, c_-^{-1} \sigma_-^2) \text{ and } \epsilon_{j+} \stackrel{iid}{\sim} N(0, c_+^{-1} \sigma_+^2)$$

Model parameters are estimated as

$$\begin{aligned}\hat{\beta}_- &= (\bar{\mathbf{X}}_-'\bar{\mathbf{X}}_-)^{-1}\bar{\mathbf{X}}_-' \mathbf{Y}_- \\ \hat{\beta}_+ &= (\bar{\mathbf{X}}_+' \bar{\mathbf{X}}_+)^{-1}\bar{\mathbf{X}}_+' \mathbf{Y}_+ \\ \hat{\sigma}_-^2 &= c_-(J_- - p)^{-1}\mathbf{Y}_-'(\mathbf{I} - \mathbf{H}_-)\mathbf{Y}_- \\ \hat{\sigma}_+^2 &= c_+(J_+ - p)^{-1}\mathbf{Y}_+'(\mathbf{I} - \mathbf{H}_+)\mathbf{Y}_+\end{aligned}$$

where

- $\bar{\mathbf{X}}_- = (\bar{\mathbf{X}}_{1-}, \dots, \bar{\mathbf{X}}_{J-})'$ and $\bar{\mathbf{X}}_+ = (\bar{\mathbf{X}}_{1+}, \dots, \bar{\mathbf{X}}_{J++})'$
- $\mathbf{Y}^- = (Y_{1-}, \dots, Y_{J-})'$ and $\mathbf{Y}^+ = (Y_{1+}, \dots, Y_{J++})'$
- $\mathbf{H}_- = \bar{\mathbf{X}}_-(\bar{\mathbf{X}}_-' \bar{\mathbf{X}}_-)^{-1}\bar{\mathbf{X}}_-'$ and $\mathbf{H}_+ = \bar{\mathbf{X}}_+(\bar{\mathbf{X}}_+' \bar{\mathbf{X}}_+)^{-1}\bar{\mathbf{X}}_+'$
- \mathbf{I} is the identity matrix

Parameter estimation

Under our modeling assumptions, it is easy to show that

$$\hat{\beta}_- \sim N\left(\beta_-, c_-^{-1} \sigma_-^2 (\bar{\mathbf{X}}_-' \bar{\mathbf{X}}_-)^{-1}\right)$$

$$\hat{\beta}_+ \sim N\left(\beta_+, c_+^{-1} \sigma_+^2 (\bar{\mathbf{X}}_+' \bar{\mathbf{X}}_+)^{-1}\right)$$

and

$$\frac{(J_- - p) \hat{\sigma}_-^2}{\sigma_-^2} \sim \chi_{J_- - p}^2$$

$$\frac{(J_+ - p) \hat{\sigma}_+^2}{\sigma_+^2} \sim \chi_{J_+ - p}^2$$

Consequently, it is possible to conduct typical regression diagnostics, hypothesis tests, and inference

- Let $\boldsymbol{\theta} = (\beta_+, \beta_-, \sigma_+^2, \sigma_-^2)'$ denote the model parameters
- Let $\hat{\boldsymbol{\theta}} = (\hat{\beta}_+, \hat{\beta}_-, \hat{\sigma}_+^2, \hat{\sigma}_-^2)'$ denote their estimates

Covariate adjusted sensitivities and specificities:

$$S_e(\mathbf{X}, t, \boldsymbol{\theta}) = \Phi\left(\frac{\mathbf{X}'\boldsymbol{\beta}_+ - t}{\sigma_+}\right) \quad \text{and} \quad S_p(\mathbf{X}, t, \boldsymbol{\theta}) = \Phi\left(\frac{t - \mathbf{X}'\boldsymbol{\beta}_-}{\sigma_-}\right)$$

Covariate adjusted Youden index:

$$\text{YI}(\mathbf{X}, \boldsymbol{\theta}) = \sup_{t \in \mathbb{R}} \left\{ \Phi\left(\frac{\mathbf{X}'\boldsymbol{\beta}_+ - t}{\sigma_+}\right) + \Phi\left(\frac{t - \mathbf{X}'\boldsymbol{\beta}_-}{\sigma_-}\right) - 1 \right\}$$

Covariate adjusted optimal cut point:

$$t_0(\mathbf{X}, \boldsymbol{\theta}) = \operatorname{argmax}_{t \in \mathbb{R}} \left\{ \Phi\left(\frac{\mathbf{X}'\boldsymbol{\beta}_+ - t}{\sigma_+}\right) + \Phi\left(\frac{t - \mathbf{X}'\boldsymbol{\beta}_-}{\sigma_-}\right) - 1 \right\}$$

Covariate adjusted AUC:

$$\text{AUC}(\mathbf{X}, \boldsymbol{\theta}) = \Phi\left(\frac{\mathbf{X}'\boldsymbol{\beta}_+ - \mathbf{X}'\boldsymbol{\beta}_-}{\sqrt{\sigma_+^2 + \sigma_-^2}}\right)$$

Estimates of the covariate adjusted Youden index, optimal cutpoint, and AUC can be obtained as

$$YI(\mathbf{X}, \hat{\boldsymbol{\theta}}), \quad t_0(\mathbf{X}, \hat{\boldsymbol{\theta}}), \quad AUC(\mathbf{X}, \hat{\boldsymbol{\theta}})$$

Further, we establish that at a given predictor level \mathbf{X}

$$\begin{aligned}\sqrt{J}\{\widehat{YI}(\mathbf{X}, \hat{\boldsymbol{\theta}}) - YI(\mathbf{X}, \boldsymbol{\theta})\} &\xrightarrow{d} N(0, \Sigma_{YI}) \\ \sqrt{J}\{\widehat{t_0}(\mathbf{X}, \hat{\boldsymbol{\theta}}) - t_0(\mathbf{X}, \boldsymbol{\theta})\} &\xrightarrow{d} N(0, \Sigma_{t_0}) \\ \sqrt{J}\{\widehat{AUC}(\mathbf{X}, \hat{\boldsymbol{\theta}}) - AUC(\mathbf{X}, \boldsymbol{\theta})\} &\xrightarrow{d} N(0, \Sigma_{AUC})\end{aligned}$$

- The above expressions assume that $J_- = J_+ = J$
- Closed form expressions (along with their finite sample estimators) of the asymptotic variances (i.e., Σ_{YI} , Σ_{t_0} , and Σ_{AUC}) were also obtained

To simultaneously assess a biomarker across the entire covariate space we derive asymptotic $100(1 - \alpha)\%$ confidence bands for $\text{AUC}(\mathbf{X}, \boldsymbol{\theta})$; i.e., the sets $C(\mathbf{X})$ can be constructed such that

$$\text{pr} \{ \text{AUC}(\mathbf{X}, \boldsymbol{\theta}) \in C(\mathbf{X}) \text{ for all } \mathbf{X} \} = 1 - \alpha.$$

Sets of this form can be constructed as

$$C(\mathbf{X}) = \left[\Phi \left(\frac{\mathbf{x}'(\hat{\boldsymbol{\beta}}^+ - \hat{\boldsymbol{\beta}}^-)}{\sqrt{\hat{\sigma}_+^2 + \hat{\sigma}_-^2}} - \sqrt{\chi_{p,1-\alpha}^2} \sqrt{\hat{\Sigma}_{\text{AUC}^*}} \right), \Phi \left(\frac{\mathbf{x}'(\hat{\boldsymbol{\beta}}^+ - \hat{\boldsymbol{\beta}}^-)}{\sqrt{\hat{\sigma}_+^2 + \hat{\sigma}_-^2}} + \sqrt{\chi_{p,1-\alpha}^2} \sqrt{\hat{\Sigma}_{\text{AUC}^*}} \right) \right],$$

where

- $\chi_{p,1-\alpha}^2$ denotes the $1 - \alpha$ th quantile of a chi-squared distribution with p degrees of freedom
- $\hat{\Sigma}_{\text{AUC}^*}$ is an asymptotic variance estimator whose explicit form is provided in our manuscript


Simulation settings:

Control model: $Y_{k-} = \mathbf{X}'_{k-}\boldsymbol{\beta}_- + \epsilon_{k-}$ for $k = 1, \dots, N$,

Case model: $Y_{k+} = \mathbf{X}'_{k+}\boldsymbol{\beta}_+ + \epsilon_{k+}$ for $k = 1, \dots, N$,


- $\mathbf{X}_{k+} = (1, X_{k1+})'$ and $X_{k1+} \sim N(225, 40^2)$
- $\mathbf{X}_{k-} = (1, X_{k1-})'$ and $X_{k1-} \sim N(205, 40^2)$
- $\epsilon_{k+} \sim N(0, 2.15^2)$, and $\epsilon_{k-} \sim N(0, 1.35^2)$
- $\boldsymbol{\beta}_+ = (1.750, 0.015)'$ and $\boldsymbol{\beta}_- = (3.000, -0.005)'$
- Sample sizes: $N \in \{40, 80, 160\}$
- Pool sizes: $c_- = c_+ = c \in \{1, 2, 4\}$
- Two pooling schemes: Random pooling (RP) and homogeneous pooling (HP)
- Replications: For each (c, N) combination and pooling scheme 10,000 data sets were generated and analyzed

Simulation study



- Top to bottom: $t_0(\mathbf{X}, \boldsymbol{\theta})$, $YI(\mathbf{X}, \boldsymbol{\theta})$, and $AUC(\mathbf{X}, \boldsymbol{\theta})$
- Left to right: $N=40$, 80 , and 160

Simulation study




- Top to bottom: $t_0(\mathbf{X}, \theta)$, $YI(\mathbf{X}, \theta)$, and $AUC(\mathbf{X}, \theta)$
- Left to right: $N=40, 80, \text{ and } 160$


Data application

- ❑ Interleukin-6 (IL-6) is a pro-inflammatory cytokine that has been related to a host of biological functions, including coronary heart disease
- ❑ High levels of cholesterol are also associated with coronary heart disease
- ❑ This analysis considers 40 cases who had recently had a myocardial infarction (MI), and 40 controls
- ❑ Cholesterol and IL-6 were measured on all 80 subjects individually
- ❑ IL-6 was also assessed on pools of size two and four under RP
- ❑ For comparative purposes, we also consider artificially implementing HP
- ❑ A first order linear model was fit to the case and control data separately, using cholesterol as the only predictor variable

Results of data analysis: Observed data



Results of data analysis: Artificial HP



Discussion and future work

- ❑ Developed regression methodology for pooled biomarker measurements
- ❑ The proposed methodology allows one to estimate and perform inference about several common covariate dependent measures of discrimination; i.e., ROC, YI, AUC, and t_0
- ❑ Through additional simulation studies, we have discovered that our proposed techniques are relatively robust to departures from normality
- ❑ Future work includes, but is not limited to:
 - ❑ Extending the methodology proposed here to the class of generalized linear models
 - ❑ Develop nonparametric/semiparametric alternatives
 - ❑ Generalize to allow for the analysis of multiple biomarkers simultaneously
 - ❑ Account for common issues; e.g., measurement error, limits of detection, etc.